The Importance of Proteasome Inhibitors in Myeloma and Their Evolution in the New Age of Myeloma Therapy with Dr. Jacob Laubach, MD, MPP, Dana Farber Cancer Institute

Dr. Jacob Laubach, MD is an Assistant Professor in Medicine at Harvard Medical School and the Clinical Director of the Jerome Lipper Multiple Myeloma Center at Dana Farber Cancer Institute. Dr. Laubach completed his medical degree, residency and fellowship in hematology at Duke University Medical Center in Durham, NC. He joined the Dana Farber Cancer Institute faculty in 2008. Since joining the Dana Farber Cancer Institute faculty in 2008, he has been dedicated to the growth and expansion of the Multiple Myeloma clinical program and to clinical research evaluating new therapeutic agents in Multiple Myeloma. As a clinician, he has a large academic practice focused on the care of patients with plasma cell disorders. In addition, Dr. Laubach played a lead role in the formation of a multi-disciplinary Amyloidosis program at DFCI and Brigham & Women’s Hospital and serving as associate director before being succeeded by Dr. Giada Bianchi in 2018. As a clinical investigator, his research has focused primarily on the development of new therapeutic agents. Dr. Laubach has been involved in the study of histone deacetylase inhibition as a treatment strategy in Multiple Myeloma and in the development of monoclonal antibodies in this disease such as CS-1 (Elotuzumab) and CD38 (Daratumuab). He is currently leading an international phase 2 trial evaluating subcutaneous bortezomib as a component of the standard of care induction regiment lenalidomide, bortezomib, and dexamethasone and was a lead investigator in the recently published GRIFFIN trial evaluating the combination of daratumumab plus RVD. He has also been involved in efforts through the International Myeloma Working Group to update guidelines on management of relapsed and refractory myeloma. Dr. Laubach’s clinical practice has provided frequent opportunities for teaching and mentoring students at Harvard Medical School, Residents at Brigham & Women’s Hospital, and Fellows in the Dana-Farber/Partners CancerCare Hematology/Oncology Fellowship Program.

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.